In yesterday’s Wall Street session, Evelo Biosciences Inc. (NASDAQ:EVLO) shares traded at $9.86, up 52.40% from the previous session.
As of this writing, 3 analysts cover Evelo Biosciences Inc. (NASDAQ:EVLO). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $40.00 and a low of $20.00, we find $30.00. Given the previous closing price of $6.47, this indicates a potential upside of 363.68 percent. EVLO stock price is now 228.09% away from the 50-day moving average and -47.01% away from the 200-day moving average. The market capitalization of the company currently stands at $163.92M.
There are 2 analysts who have given it a hold rating, whereas 1 have given it a buy rating. Brokers who have rated the stock have averaged $30.00 as their price target over the next twelve months.
With the price target maintained at $12, Chardan Capital Markets recently Upgraded its rating from Neutral to Buy for Evelo Biosciences Inc. (NASDAQ: EVLO).
In other news, Flagship Ventures Fund IV Gene, 10% Owner bought 5,411,255 shares of the company’s stock on Jul 11. The stock was bought for $12,499,999 at an average price of $2.31. Upon completion of the transaction, the 10% Owner now directly owns 3,931,685 shares in the company, valued at $38.77 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 23, CSO, President of R&D Bodmer Mark sold 22,571 shares of the business’s stock. A total of $3,201 was realized by selling the stock at an average price of $0.14. This leaves the insider owning 262,557 shares of the company worth $2.59 million. Insiders disposed of 176,963 shares of company stock worth roughly $1.74 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in EVLO stock. A new stake in Evelo Biosciences Inc. shares was purchased by JEFFERIES FINANCIAL GROUP INC. during the first quarter worth $37,000. MAN GROUP PLC invested $26,000 in shares of EVLO during the first quarter. In the first quarter, VIRTU FINANCIAL LLC acquired a new stake in Evelo Biosciences Inc. valued at approximately $12,000. SIMPLEX TRADING, LLC acquired a new stake in EVLO for approximately $1,000.
Thursday morning saw Evelo Biosciences Inc. (NASDAQ: EVLO) opened at $6.35. During the past 12 months, Evelo Biosciences Inc. has had a low of $0.49 and a high of $65.80. The fifty day moving average price for EVLO is $3.15 and a two-hundred day moving average price translates $18.45 for the stock.
The latest earnings results from Evelo Biosciences Inc. (NASDAQ: EVLO) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$4.6, missing analysts’ expectations of -$3.16 by -1.44. This compares to -$11.14 EPS in the same period last year. The company reported revenue of $24.9 million for the quarter, compared to $28.74 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -13.36 percent.
Evelo Biosciences Inc.(EVLO) Company Profile
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
